PURPOSE: Indenoisoquinolines are non-camptothecin topoisomerase I (TopI) inhibitors that overcome the limitations of camptothecins: chemical instability and camptothecin resistance. Two dosing schedules of the novel indenoisoquinoline, indotecan (LMP400), were evaluated in patients with advanced solid tumors. METHODS: The maximum tolerated dose (MTD), toxicities, and pharmacokinetics of two indotecan drug administration schedules (daily for 5 days or weekly) were investigated. Modulation of TopI and the phosphorylation of histone H2AX (γH2AX) were assayed in tumor biopsies; γH2AX levels were also evaluated in circulating tumor cells (CTCs) and hair follicles to assess DNA damage response. RESULTS: An MTD of 60 mg/m(2)/day was established for the daily regimen, compared to 90 mg/m(2) for the weekly regimen. The TopI response to drug showed target engagement in a subset of tumor biopsies. Pharmacokinetics profiles demonstrated a prolonged terminal half-life and tissue accumulation compared to topotecan. Dose-dependent decreases in total CTCs were measured in seven patients. Formation of γH2AX-positive foci in CTCs (day 3) and hair follicles (4-6 h) was observed following treatment. CONCLUSIONS: We established the MTD of two dosing schedules for a novel TopI inhibitor, indotecan. Target engagement was demonstrated as Top1 downregulation and γH2AX response. No objective responses were observed on either schedule in this small patient cohort. The principal toxicity of both schedules was myelosuppression; no significant gastrointestinal problems were observed. Increased DNA damage response was observed in CTCs, hair follicles, and a subset of tumor biopsies.
PURPOSE:Indenoisoquinolines are non-camptothecin topoisomerase I (TopI) inhibitors that overcome the limitations of camptothecins: chemical instability and camptothecin resistance. Two dosing schedules of the novel indenoisoquinoline, indotecan (LMP400), were evaluated in patients with advanced solid tumors. METHODS: The maximum tolerated dose (MTD), toxicities, and pharmacokinetics of two indotecan drug administration schedules (daily for 5 days or weekly) were investigated. Modulation of TopI and the phosphorylation of histone H2AX (γH2AX) were assayed in tumor biopsies; γH2AX levels were also evaluated in circulating tumor cells (CTCs) and hair follicles to assess DNA damage response. RESULTS: An MTD of 60 mg/m(2)/day was established for the daily regimen, compared to 90 mg/m(2) for the weekly regimen. The TopI response to drug showed target engagement in a subset of tumor biopsies. Pharmacokinetics profiles demonstrated a prolonged terminal half-life and tissue accumulation compared to topotecan. Dose-dependent decreases in total CTCs were measured in seven patients. Formation of γH2AX-positive foci in CTCs (day 3) and hair follicles (4-6 h) was observed following treatment. CONCLUSIONS: We established the MTD of two dosing schedules for a novel TopI inhibitor, indotecan. Target engagement was demonstrated as Top1 downregulation and γH2AX response. No objective responses were observed on either schedule in this small patient cohort. The principal toxicity of both schedules was myelosuppression; no significant gastrointestinal problems were observed. Increased DNA damage response was observed in CTCs, hair follicles, and a subset of tumor biopsies.
Entities:
Keywords:
DNA damage; DNA topoisomerase I; H2AX protein; Hair follicle; Indenoisoquinolines; NSC 743400
Authors: Julianne L Holleran; Robert A Parise; Archibong E Yellow-Duke; Merrill J Egorin; Julie L Eiseman; Joseph M Covey; Jan H Beumer Journal: J Pharm Biomed Anal Date: 2010-02-23 Impact factor: 3.935
Authors: Christophe E Redon; Asako J Nakamura; Ksenia Gouliaeva; Arifur Rahman; William F Blakely; William M Bonner Journal: PLoS One Date: 2010-11-23 Impact factor: 3.240
Authors: Maris A Cinelli; P V Narasimha Reddy; Peng-Cheng Lv; Jian-Hua Liang; Lian Chen; Keli Agama; Yves Pommier; Richard B van Breemen; Mark Cushman Journal: J Med Chem Date: 2012-12-07 Impact factor: 7.446
Authors: Michael S Braun; Susan D Richman; Philip Quirke; Catherine Daly; Julian W Adlard; Faye Elliott; Jennifer H Barrett; Peter Selby; Angela M Meade; Richard J Stephens; Mahesh K B Parmar; Matthew T Seymour Journal: J Clin Oncol Date: 2008-06-01 Impact factor: 44.544
Authors: Thomas D Pfister; William C Reinhold; Keli Agama; Shalu Gupta; Sonny A Khin; Robert J Kinders; Ralph E Parchment; Joseph E Tomaszewski; James H Doroshow; Yves Pommier Journal: Mol Cancer Ther Date: 2009-07-07 Impact factor: 6.261
Authors: Chen Shao; Chun-Peng Liao; Peizhen Hu; Chia-Yi Chu; Lei Zhang; Matthew H T Bui; Christopher S Ng; David Y Josephson; Beatrice Knudsen; Mourad Tighiouart; Hyung L Kim; Haiyen E Zhau; Leland W K Chung; Ruoxiang Wang; Edwin M Posadas Journal: PLoS One Date: 2014-02-14 Impact factor: 3.240
Authors: Daniel E Beck; Keli Agama; Christophe Marchand; Adel Chergui; Yves Pommier; Mark Cushman Journal: J Med Chem Date: 2014-02-11 Impact factor: 7.446
Authors: Jenna H Burton; Christina Mazcko; Amy LeBlanc; Joseph M Covey; Jiuping Ji; Robert J Kinders; Ralph E Parchment; Chand Khanna; Melissa Paoloni; Sue Lana; Kristen Weishaar; Cheryl London; William Kisseberth; Erika Krick; David Vail; Michael Childress; Jeffrey N Bryan; Lisa Barber; E J Ehrhart; Michael Kent; Timothy Fan; Kelvin Kow; Nicole Northup; Heather Wilson-Robles; Joseph Tomaszewski; Julianne L Holleran; Miguel Muzzio; Julie Eiseman; Jan H Beumer; James H Doroshow; Yves Pommier Journal: Clin Cancer Res Date: 2018-07-30 Impact factor: 12.531
Authors: Mohamed S A Elsayed; Yafan Su; Ping Wang; Taresh Sethi; Keli Agama; Azhar Ravji; Christophe E Redon; Evgeny Kiselev; Katharine A Horzmann; Jennifer L Freeman; Yves Pommier; Mark Cushman Journal: J Med Chem Date: 2017-06-28 Impact factor: 7.446
Authors: Florence Coussy; Rania El-Botty; Sophie Château-Joubert; Ahmed Dahmani; Elodie Montaudon; Sophie Leboucher; Ludivine Morisset; Pierre Painsec; Laura Sourd; Léa Huguet; Fariba Nemati; Jean-Luc Servely; Thibaut Larcher; Sophie Vacher; Adrien Briaux; Cécile Reyes; Philippe La Rosa; Georges Lucotte; Tatiana Popova; Pierre Foidart; Nor Eddine Sounni; Agnès Noel; Didier Decaudin; Laetitia Fuhrmann; Anne Salomon; Fabien Reyal; Christopher Mueller; Petra Ter Brugge; Jos Jonkers; Marie-France Poupon; Marc-Henri Stern; Ivan Bièche; Yves Pommier; Elisabetta Marangoni Journal: Sci Transl Med Date: 2020-02-19 Impact factor: 17.956
Authors: Laetitia Marzi; Keli Agama; Junko Murai; Simone Difilippantonio; Amy James; Cody J Peer; William D Figg; Daniel Beck; Mohamed S A Elsayed; Mark Cushman; Yves Pommier Journal: Mol Cancer Ther Date: 2018-05-10 Impact factor: 6.261